Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 13/20 | 0.49 |
| ▸ | RARB | P10826 | 13/20 | 0.49 |
| ▸ | RARG | P13631 | 13/20 | 0.49 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.49 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 5/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | RXRG | P48443 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6339573 | 0.89 | RARB (0.49) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL6338628 | 0.89 | RARB (0.53) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL6341002 | 0.78 | RARB (0.54) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL6340794 | 0.76 | RARG (0.36) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL1406518 | 0.76 | RARB (0.51) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL7752262 | 0.76 | RXRA (0.64) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL6343265 | 0.76 | RARB (0.47) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL6341768 | 0.74 | RARB (0.46) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL6350620 | 0.74 | RARB (0.44) | RARARARBRARGCYP26A1CYP3A4 | |
| SCHEMBL6339579 | 0.74 | RARB (0.45) | RARARARBRARGCYP26A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030216586-A1 | Biaromatic compounds and pharmaceutical and cosmetic compositions comprising them | GALDERMA RESEARCH & DEVELOPMENT | 2003-11-20 | — | — | US | claimed |
| EP-0977749-B1 | BI-AROMATIC COMPOUNDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | GALDERMA RES & DEV (FR) | 2002-03-13 | — | — | EP | claimed |
| US-6103762-A | A BIAROMATIC COMPOUNDS IN WHICH THE AROMATIC NUCLEI ARE CONNECTED BY A PROPYNYLENE OR ALLENYLENE DIVALENT RADICAL, USEFUL AS HUMAN OR VETERINARY MEDICINE OR USED IN COSMETICS OR KERATINIZATION DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2000-08-15 | — | — | US | claimed |
| US-6849658-B2 | Biaromatic compounds and pharmaceutical and cosmetic compositions comprising them | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2005-02-01 | — | — | US | disclosed |
| US-20030216586-A1 | Biaromatic compounds and pharmaceutical and cosmetic compositions comprising them | GALDERMA RESEARCH & DEVELOPMENT | 2003-11-20 | — | — | US | disclosed |
| US-6346546-B1 | COMPOUNDS HAVING MARKED ACTIVITY IN FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION; TREATING SKIN DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2002-02-12 | — | — | US | disclosed |
| US-6103762-A | A BIAROMATIC COMPOUNDS IN WHICH THE AROMATIC NUCLEI ARE CONNECTED BY A PROPYNYLENE OR ALLENYLENE DIVALENT RADICAL, USEFUL AS HUMAN OR VETERINARY MEDICINE OR USED IN COSMETICS OR KERATINIZATION DISORDERS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2000-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216586-A1 | Biaromatic compounds and pharmaceutical and cosmetic compositions comprising them | AR, SRR, MC3R | RARA 47/4885RARB 120/4885RARG 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.